[go: up one dir, main page]

WO2014174073A1 - Formulations de tofacitinib à libération prolongée - Google Patents

Formulations de tofacitinib à libération prolongée Download PDF

Info

Publication number
WO2014174073A1
WO2014174073A1 PCT/EP2014/058448 EP2014058448W WO2014174073A1 WO 2014174073 A1 WO2014174073 A1 WO 2014174073A1 EP 2014058448 W EP2014058448 W EP 2014058448W WO 2014174073 A1 WO2014174073 A1 WO 2014174073A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
tofacitinib
formulations
release
mpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/058448
Other languages
English (en)
Inventor
Zrinka Abramovic
Uros Klancar
Bostjan MARKUN
Igor Legen
Klemen Naversnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of WO2014174073A1 publication Critical patent/WO2014174073A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Definitions

  • the present invention relates to sustained release formulations for oral administration comprising tofacitinib or a pharmaceutically acceptable salt thereof.
  • Tofacitinib 3- ⁇ (3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- amino]-piperidin-l -yl ⁇ 3-oxo-propionitrile, is an inhibitor of the enzyme Janus Kinase 3 (JAK3) indicated for treatment of rheumatoid arthritis. Its synthetic preparation is disclosed in WO 02/096909 Al, WO 03/048162 Al and WO 2007/012953 A2.
  • the recommended dose is 5 mg given orally twice daily.
  • the FDA label contains a black-box warning alerting about the risk of serious side effects, such as serious infections (tuberculosis, invasive fungal and viral infections), lymphoma and other malignancies. Serious concerns about the risk of malignancy with 10 mg dose were raised by the FDA and eventually this dosage was not approved.
  • the risk of serious side effects increases in a dose and time-dependant fashion. An increased frequency of side effects of drugs is usually observed when peak plasma concentrations exceed a certain level.
  • Tofacitinib exhibits linear pharmacokinetics, with the systemic exposure (AUCM) and peak plasma concentration (Cmax) increasing in proportion to the dose in the dose range of 1 to 100 mg.
  • peak plasma concentrations of the 10 mg tofacitinib dose are approximately two times higher than those of the 5 mg dose and they may be too high for a safe drug administration.
  • Plasma concentration of Tofacitinib after oral administration is directly related to the release rate of the drug in the gastrointestinal tract.
  • IR immediate release
  • Sustained peak plasma concentrations can theoretically be achieved by means of sustained release matrix systems. However, when such systems are made of hydrophilic polymers, they seldom provide pH independent drug release of pH-dependent soluble drugs and they are normally incapable of attaining zero-order release except for practically insoluble drugs. From FDA published data it can be seen that the aqueous solubility of Tofacitinib citrate is pH-dependent with higher solubility at low pH and drastically decreased solubility at pH above 3.9. pH dependent solubility can lead to pH-dependent in vivo drug release from sustained release matrices. Drug release varies as a function of movement through segments of the gastrointestinal tract with different pH. This can lead to inefficient drug delivery and bigger inter-subject variability, since pH in the gastrointestinal tract varies significantly between subjects. Sustained release formulations that would provide pH independent drug release throughout whole gastrointestinal tract are very desirable.
  • the robustness of drug release is also critical, since mechanical stress applied to matrix tablets during gastrointestinal transit may lead to faster disruption of the gel layer and influence the plasma drug concentrations over time. This can change the therapeutic efficacy and safety.
  • Different mechanical stress can be exerted on matrix tablets due to variety of gastrointestinal conditions.
  • MMC migrating myoelectric complex
  • the movement of tablets during this phase is rapid and tablets are subject to increased mechanical stress, especially during gastric emptying.
  • gastrointestinal motility is elevated during and after food intake. This causes even greater mechanical stress on pharmaceutical compositions.
  • food intake stimulates the transport of gastrointestinal content from the terminal small intestine into the colon, a mechanism that is known as gastro-ileal or gastro-ileocecal reflex, which can again exert elevated mechanical stress on the matrix tablet.
  • WO 2012/100949 Al discloses oral dosage forms for modified release comprising Tofacitinib. Such formulations are disclosed in very general terms and give no direction to the skilled man for preparing sustained formulations with adequate release profile and properties. 10 examples of specific formulations are also provided, but no dissolution test results. When reproduced, such formulations showed poor release properties, liberating the active ingredient too fast for any practical application, and proved not to be resistant to mechanical stress.
  • the present disclosure provides a sustained release formulation for oral administration comprising tofacitinib or a pharmaceutically acceptable salt thereof, a hydrophilic polymer and an alkalizing agent, wherein the pH at 25 °C of a 1% weight/volume water solution or dispersion of the formulation is between 5.5 and 11. It further provides a sustained release formulation for oral administration comprising tofacitinib or a pharmaceutically acceptable salt thereof and a polymer, wherein the hydrophilic polymer is either a cellulose derivative with a viscosity between 1000 and 150000 mPa-s, a carrageenan with a viscosity of 5 mPa-s or higher or a mixture thereof.
  • a once daily dosage regimen of the formulations of the invention preferably for the treatment of rheumatoid arthritis, is also disclosed.
  • FIG. 1 illustrates simulated plasma profiles after twice daily administration of immediate release formulations containing 5 mg and 10 mg of tofacitinib (full and dashed line) and once daily administration of a sustained release formulation containing 11 mg of Tofacitinib (dotted line).
  • FIG. 2 illustrates the stability profile of Tofacitinib citrate at various pH.
  • FIG. 3 illustrates the dissolution test results of the formulations of example 1 (25% HPMC without alkalizing agent) - top - and example 15 (60 % of HEC without alkalizing agent) - bottom - using apparatus 2 at 100 rpm and dissolution media with different pH: dashed line at pH 1.2 + 6.8; full line at pH 6.8.
  • FIG. 4 illustrates the dissolution test results of the formulation of example 2 (25% HPMC with insoluble alkalizing agents) using apparatus 2 at 100 rpm and dissolution media with different pH: dashed line at pH 1.2 + 6.8; full line at pH 6.8.
  • FIG. 5 illustrates the dissolution test results of the formulations of example 3 (25% HPMC with 9 % sodium citrate) - top - and of example 5 (25%> HPMC with 48 % sodium citrate) - bottom -using apparatus 2 at 100 rpm and dissolution media with different pH: dashed line at pH 1.2 + 6.8; full line at pH 6.8.
  • FIG. 6 illustrates the dissolution test results of the formulation of example 8b (60% HEC with 25 % sodium citrate) using apparatus 2 at 100 rpm and dissolution media with different pH: dashed line at pH 1.2 + 6.8; full line at pH 6.8.
  • FIG. 7 illustrates the dissolution test results of the formulations of example 9 (25%> HPMC with calcium hydrogen phosphate dihydrate) - top - and 10 (25% HPMC with calcium sulphate) - bottom - using apparatus 2 at 100 rpm and dissolution media with different pH: dashed line at pH 1.2 + 6.8; full line at pH 6.8.
  • FIG. 8 illustrates the dissolution test results of the formulations of examples 11-13 (15 % circle, 25 % triangle and 35 > diamond HPMC) with (dotted lines) or without mechanical stress (full lines) using apparatus 1, 100 RPM, 900 ml of pH 6.8 medium.
  • FIG. 9 illustrates the dissolution test results of the formulations of examples 14 and 15 (30 % circle, 60% diamond HEC) with (dotted lines) or without mechanical stress (full lines) using apparatus 1, 100 RPM, 900 ml of pH 6.8 medium.
  • FIG. 10 illustrates the dissolution test results of the formulations of example 2 (25 % HPMC with insoluble alkalizing agents) with (dotted lines) or without mechanical stress (full lines) using apparatus 1 , 100 RPM, 900 ml of pH 6.8 medium.
  • FIG. 11 illustrates the dissolution test results of the formulations of example 17 (HEC + carrageenan) using apparatus 2 at 100 rpm and dissolution media with different pH (dotted line pH 1.2 + 6.8; full line 6.8 ) - top - and with (dotted line) or without mechanical stress (full line) using Apparatus 1, 100 RPM, 900 ml of pH 6.8 medium - bottom -.
  • FIG. 12 illustrates a schematic view of a hydrophilic matrix bilayer tablet comprising the active pharmaceutical ingredient (API) tofacitinib and a sustained release (SR) polymer.
  • API active pharmaceutical ingredient
  • SR sustained release
  • hydrophilic polymer refers to water soluble polymeric materials that in contact with an aqueous environment swell and form a gel matrix. They are characterized by the presence of polar groups attached to the main polymer backbone of the molecule (see C.A. Finch: Hydrophilic polymers. In: R.W.Dyson (ed.) Specialty Polymers; Blackie&Son Ltd 1987).
  • alkalizing agent refers to any agent that counteracts or neutralizes acidity and/or increases the concentration of hydroxide anions (OH ) in water.
  • An ideal sustained release formulation releases the drug with a constant rate between 4 and 18 hours, preferably over 16 hours (zero-order release), and provides effective drug plasma concentration levels over a longer period of time, while at the same time not exceeding the peak plasma concentration of the immediate release formulation, as shown in FIG.l . This results in improved safety and efficacy of the drug product.
  • the plasma concentration is then obtained by dividing the amount of drug A by the volume of distribution V d .
  • the drug is completely absorbed with about 20% of first-pass elimination.
  • the absorption rate for the immediate release formulation is dictated by the transit of drug from the stomach into the intestine, where the absorption takes place.
  • the dissolution rate for the sustained release formulation was chosen to mimic the preferred constant (i.e
  • sustained release formulation has to be carefully developed to provide drug release that would give optimal plasma concentrations and at the same time be robust enough to prevent dose dumping or a high burst effect. Both phenomena cause the premature and exaggerated release of a drug that can greatly increase its concentration in the body and thereby produce adverse effects. Dose dumping can be a consequence of poor sustained release formulation and several in vivo factors such as mechanical stress in the gastrointestinal tract (i.e. passage of formulation from the stomach into the duodenum and from the ileum to the colon), presence of food or alcohol in the stomach, differences in pH along the
  • Burst release is a phenomenon where an initial large bolus of drug is released before the release rate reaches a stable profile. It is related to some formulations (e.g. hydrophilic matrix systems) and well soluble drugs (S. B. Tiwari, A. R. Rajabi-Siahboomi, "Extended-release oral drug delivery technologies: Monolithic Matrix systems ", Methods in Molecular Biology, Drug Delivery Systems, Vol. 437, 217-243.).
  • one object of the present invention is the provision of Tofacitinib formulations causing reduced drug level fluctuation in plasma.
  • Another object of the present invention is the provision of formulations of Tofacitinib with reduced side effects.
  • Another object of the present invention is the provision of Tofacitinib formulations with pH independent release avoiding a burst at the acidic pH of the stomach.
  • Another object of the present invention is the provision of Tofacitinib formulations that are mechanically robust.
  • Another object of the present invention is the provision of Tofacitinib formulations that prevent dose dumping or a high burst effect.
  • Another object of the present invention is the provision of Tofacitinib formulations that do not show a food effect.
  • Another object of the present invention is the provision of Tofacitinib formulations with a zero order release profile.
  • Another object of the present invention is the provision of a dosage regimen for Tofacitinib with improved patient compliance.
  • One embodiment of the present invention is a sustained release formulation for oral administration comprising tofacitinib or a pharmaceutically acceptable salt thereof, a hydrophilic polymer and an alkalizing agent, wherein the pH at 25°C of a 1% weight/volume water solution or dispersion of the formulation is between 5.5 and 11.
  • Another embodiment of the present invention is a sustained release formulation for oral administration comprising tofacitinib or a pharmaceutically acceptable salt thereof and a hydrophilic polymer, wherein the hydrophilic polymer is either a cellulose derivative with a viscosity between 1000 and 150000 mPa-s, a carrageenan with a viscosity greater than 5 mPa-s or a mixture thereof.
  • Formulations of the invention are matrix formulations where a rate-controlling hydrophilic polymer forms a matrix through which the drug is dissolved or dispersed.
  • Such formulations can be in the form of tablets, minitablets (that can be further inserted in capsules), pellets and granules, preferably in the form of tablets.
  • Tablets can be monolayer or multilayer, with tofacitinib included in one or more layers. Tablets can be further coated with a functional or a non-functional coating.
  • the formulations of the invention contain tofacitinib citrate.
  • the formulations of the invention comprise between 5 and 25 mg, more preferably between 20 and 22 mg or between 10 and 12 mg of tofacitinib or a pharmaceutically acceptable salt thereof, the amount being calculated based on tofacitinib free base.
  • the formulations of the invention comprise tofacitinib or a pharmaceutically acceptable salt thereof in an amount between 10 and 12 mg expressed as tofacitinib free base and, wherein such formulations are administered once a day, the Cmax of tofacitinib measured in plasma is below 35 ng/ml, preferably between 25 and 35 ng/ml.
  • Hydrophilic polymers include natural gums and polysaccharides (such as alginates, xanthan, carrageenan, locust bean gum, chitosan, guar gum, pectin, crossed-linked high amylose starch, gelatine), semisynthetic materials (such as cellulose derivatives, propylene glycol alginate) and synthetic materials (such as polyethylene oxide and homo- and copolymers of acrylic acid).
  • Preferred hydrophilic polymers are cellulose derivatives (such methylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose sodium), carrageenan and mixtures thereof.
  • Especially preferred hydrophilic polymers are hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC), carrageenan and mixtures thereof.
  • the amount of hydrophilic polymer is preferably between 15 and 80%, preferably between 20 and 70%, more preferably between 25 and 60%> w/w, based on the total weight of the pharmaceutical composition excluding any coating. If the hydrophilic polymer is present in insufficient amounts the dissolution profile is either too fast or the drug release is more easily influenced by mechanical stress. If the hydrophilic polymer is present in excessive amounts, the drug release is too slow, e.g. it could take more than 24 hours to release the drug; in addition the manufacturing of the composition may be very difficult (see figures 8 and 9).
  • the hydrophilic polymer is hydroxypropyl methylcellulose (HPMC) in an amount between 20 and 60%> w/w, more preferably between 25 and 50% w/w, based on the total weight of the pharmaceutical composition excluding any coating.
  • HPMC hydroxypropyl methylcellulose
  • the hydrophilic polymer is hydroxyethyl cellulose (HEC) in an amount between 30 and 70% w/w, more preferably between 40 and 60%> w/w, based on the total weight of the pharmaceutical composition excluding any coating.
  • HEC hydroxyethyl cellulose
  • the hydrophilic polymer is a carrageenan in an amount between 20 and 70 %, more preferably between 40 and 60% w/w, based on the total weight of the pharmaceutical composition excluding any coating.
  • the formulations of the invention comprise an alkalizing agent in order to control the solubility of the active substance and thus obtain a pH independent drug release.
  • the alkalizing agents of the invention lower the dissolution rate at pH 1.2, thus preventing the burst release due to tofacitinib ' s greater solubility in acidic media.
  • tofacitinib citrate is a very stable substance in the solid state, its solution is sensitive to alkaline pH, especially at pH 10 and above ( Figure 2). Due to such instability, alkalizing agents for tofacitinib formulations must be chosen very carefully during formulation development.
  • the pH at 25°C of a 1% weight/volume water solution or dispersion of the formulation must be between 5.5 and 11, preferably between 6 and 10.5.
  • the alkalizing agents may be soluble as well as insoluble.
  • alkalizing agents are aluminum hydroxide, bentonite, kaolin, calcium carbonate, calcium silicate, calcium hydrogen phosphate, calcium sulphate, calcium chloride, calcium lactate, sodium hydrogen carbonate, sodium stearate, sodium citrate, sodium phosphate, sodium borate, sodium lactate, sodium hyaluronate, sodium acetate, monosodium glutamate, sodium tartrate, attapulgite, potassium citrate, potassium hydrogen carbonate, potassium chloride, potassium hydrogen phosphate, tromethamine, zinc oxide, magnesium silicate, magnesium aluminum silicate, magnesium oxide, magnesium hydroxide, magnesium citrate, magnesium gluconate, dextrin, carboxymethyl cellulose sodium, carrageenan, xanthan gum and starch.
  • Preferred alkalizing agents are selected from the group consisting of salts of inorganic and organic acids. More preferred alkalizing agents are selected from the group consisting of metal oxides, metal hydroxides, salts of weak acids and some polymers that give pH of solution/dispersion in stated range. Even more preferred alkalizing agents are selected from the group consisting of magnesium oxide, calcium carbonate, calcium silicate, potassium citrate and sodium citrate and mixtures thereof. Most preferred alkalizing agents are selected from the group consisting of magnesium oxide, calcium carbonate, sodium citrate and combinations thereof. In a particularly preferred embodiment, alkalizing agents are selected from the group consisting of potassium citrate, sodium citrate and combinations thereof.
  • the amount of alkalizing agent should be sufficient to increase pH of a tablet above 5.5 and thus decrease the drug release in acidic media while at the same time providing a stable formulation.
  • Preferably such amount is between 5 and 60% w/w, more preferably between 8 and 50 %>, based on the total weight of the pharmaceutical composition excluding any coating.
  • Tofacitinib release form hydroxypropyl methylcellulose matrix tablet is faster at pH 1.2 than at pH 6.8 (figure 3 - top). Similar drug release trend was observed also for Tofacitinib formulation with
  • hydroxyethylcellulose as a matrix forming polymer (figure 3 - bottom).
  • This pH dependent drug release is most likely a consequence of pH dependent solubility of tofacitinib.
  • Sustained release formulations that show pH independent drug release of tofacitinib citrate are prepared by incorporation of the alkalizing agents of the invention. By this approach the local pH within the tablet is modified and similar dissolution profiles are obtained in phosphate buffer at 6.8 pH and hydrochloric acid dissolution medium at pH 1.2.
  • Table 1 pH and stability of tofacitinib formulations of the examples
  • alkalizing agents of the invention successfully diminishes the initial burst release of tofacitinib from matrix formulations at pH 1.2 and a similar drug release is obtained regardless of the pH of the medium.
  • calcium carbonate, magnesium oxide and calcium silicate alone or in combination successfully prevent the burst release in acidic medium (figure 4, example 2).
  • sodium citrate is used (figure 5 and 6).
  • Formulations with different quantities (9-48 %) of sodium citrate enable comparable drug release regardless of the pH of the medium ( Figure 5).
  • some formulations with calcium hydrogen phosphate or calcium sulfate do not show pH independent drug release (examples 9-10, Figure 7).
  • the viscosity of gel layer formed on the matrix in contact with water affects the erosion rate and consequently the drug release from the matrix formulation as well as determines the gel-layer robustness.
  • the viscosity of the hydrophilic polymers determines the viscosity of the formed gel layer.
  • the hydrophilic polymer is a cellulose polymer with a viscosity between 1000 and 150000 mPa-s, preferably between 2000 and 120000 mPa-s, most preferably between 2000 and 100000 mPa-s.
  • the hydrophilic polymer is hydroxypropyl methylcellulose with a viscosity between 1000 and 140000 mPa-s.
  • HPMC is available, for example, as Methocel® K4M or Kl 00M grade from Dow Chemical.
  • the hydrophilic polymer is hydroxyethylcellulose with a viscosity between 1000 and 150000 mPa-s.
  • HEC is available, for example, as Natrosol® 250 M, H or HH grade from Aqualon.
  • the hydrophilic polymer is a carrageenan with a viscosity above 5 mPa-s, more preferably between 5 and 750 mPa-s. Most preferably lambda and iota carrageenans are used.
  • Table 2 Tofacitinib release from matrix tablets with the composition of example 12 where only the viscosity grade of HPMC is varied, with (MS) or without mechanical stress (No MS) using Apparatus 1 , 100 RPM, 900 ml of pH 6.8 medium.
  • Table 3 Tofacitinib release from hydrophilic cellulose matrix tablets with the composition of example 15 where only the viscosity grade of HEC is varied, with (MS) or without mechanical stress (No MS) using Apparatus 1, 100 RPM, 900 ml of pH 6.8 medium.
  • the formulations of the invention show a pH independent drug release and are at the same time mechanically robust.
  • the formulation of example 2 when tested according to discriminatory dissolution method for mechanical robustness shows that the addition of the alkalizing agents of the invention does not negatively effects the resistance of the formulation to mechanical stress (Figure 10).
  • Formulations prepared with mixtures of cellulose and carrageenan polymers are especially preferred.
  • a particularly preferred embodiment of the present invention relates to formulations comprising hydroxyethylcellulose and carrageenan, which shows characteristics superior to those of other sustained release formulations, i.e. pH independent drug release, zero-order drug release and high robustness to mechanical stress.
  • the solubility of the drug in the polymeric matrix is a critical property that defines the drug release mechanism. For more soluble drugs the release is more diffusion controlled, for drugs with lower solubility the release is erosion controlled.
  • Drug release profiles for hydrophilic matrices are first order for highly soluble drug or zero-order for practically insoluble drugs. To obtain more zero-like drug release also for more soluble drugs like tofacitinib is more challenging with matrix formulations.
  • a particularly preferred embodiment consists of bilayer tablets. A hydrophilic polymer and Tofacitinib are combined in a first layer and an additional API free layer is applied on only one side of the first layer. The drug release from the first layer is restricted by the second layer and an initial burst effect is reduced.
  • Several formulations of the invention were prepared with different hydrophilic polymers incorporated in the second layer to achieve a zero-order drug release.
  • Q (t) is the percentage of drug released at a given time point t, k is release rate constant.
  • n can be used as a criterion to evaluate the release-mechanism kinetics and usually assumed values between 0.45 and 0.89 (for cylindrical shapes).
  • n is equal to 0.89
  • the release kinetic is of zero order, and hence, with values for n approaching 0.89, the dissolution profile of a drug becomes progressively more linear. From calculated values n it is clearly evident that the release mechanism in case of bilayer tablets is more linear compared to standard HPMC matrix tablet, as in all bilayer tablets n is greater compared to basic HPMC matrix tablet.
  • Drug release rate is also slower which is reflected in the calculated release rate constant k (Table 4).
  • Bilayer tablets were also tested for mechanical robustness. It is crucial from the safety aspect for patient that both layers are adhered well to each other and do not separate during tablet manipulation (packaging operation, taking form blister packaging or even in the gastrointestinal tract). Separation of both layers could lead to faster drug release and higher Cmax plasma concentrations. We have showed that mechanical stress during dissolution testing that simulates mechanical stress in the gastrointestinal tract does not affect the release of tofacitinib form tested tablets Table 5.
  • Table 5 Tofacitinib release from bilayer tablets of example 16 (25% HPMC in first layer) with different polymers in the second layer (A - HPMC, B - PEO, C - HEC) with (MS) or without mechanical stress (No MS) using apparatus 1, 100 RPM, 900 ml of pH 6.8 media
  • the formulations of the invention can be prepared either with wet or dry granulation or, in the case of tablets, with direct compression.
  • wet granulation low shear, high shear as well as fluid bed granulation techniques can be used.
  • aqueous solution or pure water may be utilized to prepare granulating solution.
  • the tablets were compressed using ordinary tableting equipment.
  • the size of a tablet can range from 2 to 20 mm, preferably from 8 to 13 mm for normal tablets and from 2 to 5 mm for mini tablets. Tablets can be further coated. Coating can either modulate the drug release or just provide better tablet recognition by patient (non-functional coating). In case of mini tablet they can be optionally encapsulated.
  • Formulations of the invention can further comprise further excipients, preferably selected from the group consisting of fillers, disintegrants, binders, lubricants, glidants, coloring agents and coating agents.
  • the formulations of the invention attain pH independent drug release avoiding a burst at the acidic pH of the stomach, are mechanically robust and do not show a food effect. They also prevent dose dumping or a high burst effect. They cause reduced drug level fluctuation in plasma and thus present reduced side effects. They are suitable for once-daily administration regimen and allow for improved patient compliance.
  • the viscosity of a hydrophilic polymer refers to the viscosity of a water solution containing 2 % of the hydrophilic polymer calculated on a dry basis and measured with a Brookfield viscometer at 20°C, according to the method disclosed in the USP35-NF30 S2, Chapter Hypromellose.
  • the viscosity of a carrageenan refers to the viscosity of a water solution containing 1.5 % of the carrageenan and measured using a rotational viscometer at 75°C, according to the method disclosed in the USP35-NF30 S2, Chapter Carrageenan.
  • a discriminatory dissolution method was used, which simulates gastrointestinal mechanical stress and transition through pylorus and is thus suitable to detect burst release for extended release formulations.
  • the test was performed using Apparatus 1 (basket method), 100 rpm and 900 ml phosphate buffer medium at pH 6.8. After lh 30 minutes from the beginning of the test formulations were transferred into plastic tubes containing 5 ml of medium and 15 glass beads of 8 mm diameter and were then shaken for 10 minutes on a laboratory shaker at 300 strokes per minute. Afterwards formulations were transferred back to baskets and the dissolution test continued through the remaining sampling time points. Dissolution profiles obtained from this test were compared to profiles obtained from an analogous test without the glass beads manipulation phase. To evaluate the influence of alkalizing agents, formulations were tested with a pH simulation test (pH 1.2
  • Simulation test was performed using Apparatus 2 (paddle method) at 100 rpm with JP basket sinkers to prevent floating.
  • Tofacitinib degradation products were followed by high performance liquid chromatography.
  • Formulations were dissolved in a mixture of 40 w/w% methanol in water to achieve a concentration of 0.2 mg/ml of tofacitinib.
  • the sample solution was injected into an HPLC system with a HSS T3 column (1.7 micrometer particles) using binary gradient elution.
  • Mobile phase A consisted of 0.1% trifluoroacetic acid in water and mobile phase B consisted of 50% vol. mixture of acetonitrile and mobile phase A.
  • Gradient elution was performed according to the following program: mobile phase A (%) / time (min): 80%>/0min; 0%>/8min; 80%>/8.5min.
  • the detector was set to a wavelength of 290 nm and impurities quantitated as area percentage with no response factors applied.
  • pH stability profile of Tofacitinib citrate was determined in the following manner: one ml of tofacitinib citrate solution (2 mg/ml) was pipetted into a 10 ml beaker. To this solution, 2 ml of a buffer solution was added and left to stand overnight (20-25°C, dark). Samples were then neutralized (if needed), filled to the 10 ml mark with solvent and analyzed by HPLC under the conditions described for monitoring degradation products.
  • Tofacitinib is extracted from sodium heparinized human plasma by 96-well solid phase extraction. Before the extraction, radiolabeled tofacitinib is added as an internal standard. The samples are eluted with 13% NH 4 OH in methanol, evaporated to dryness and reconstituted with 50% methanol in water. The reconstituted sample is injected into an LC/MS/MS system using a Synergi Polar-RP column with a mobile phase of 40% 10 mM ammonium acetate and 60%> methanol (with 0.05%> formic acid).
  • Core function example 1 example 2 mg/tablet mg/tablet
  • magnesium stearate All ingredients, except magnesium stearate, were mixed together and sieved through 0.75 mm mesh sieve. Then sieved (0.5 mm mesh size) magnesium stearate was added and the mixture was additionally blended. The final blend was compressed into tablets at compression forces ranging from 10 to 25 kN using round 10 or 11 mm punches.
  • Sodium citrate was first sieved through a 0.5 mm sieve. Sprayed dried lactose, microcrystalline cellulose, hydroxypropyl methylcellulose and tofacitinib citrate were mixed together and sieved through a 0.75 mm mesh sieve. Sieved sodium citrate was added and blended for 3 minutes. Then sieved (0.5 mm mesh size) magnesium stearate was added and the mixture was additionally blended. The final blend was compressed into tablets at compression forces ranging from 9 to 17 kN using round 11 mm punches.
  • Core function example 6 example 7 mg/tablet mg/tablet
  • HEC Hydrophilic cellulose
  • Core function example 9 example 10 mg/tablet mg/tablet
  • Table 1 1 Hydrophilic cellulose matrix tablets with different levels of HPMC
  • Core function example 11 example 12 example 13 mg/tablet mg/tablet mg/tablet
  • Hydroxypropyl methylcellulose matrix polymer 60.00 100.00 140.80
  • Tofacitinib citrate is mixed with part of the hydroxypropyl methylcellulose, lactose and part of the microcrystalline cellulose.
  • the mixture is granulated with water in a high shear mixer or fluid bed.
  • the granulate is dried in oven or a fluid bed dryer.
  • the dry mixture is sieved or milled through appropriate mesh size.
  • the remaining microcrystalline cellulose and hydroxypropyl methylcellulose are mixed with the granulate.
  • At the end sieved magnesium stearate is added and mixed together and tablets are compressed.
  • Core function example 14 example 15 mg/tablet mg/tablet
  • Example 14 Sprayed dried lactose, microcrystalline cellulose, hydroxyethylcellulose and tofacitinib citrate were mixed together and sieved through 0.75 mm mesh sieve. Then sieved (0.5 mm mesh size) magnesium stearate was added and the mixture was additionally blended. The final blend was compressed at compression forces ranging from 15 to 23 kN into tablets using round 10 mm punches.
  • Example 15 Tofacitinib citrate is mixed with part of the hydroxyethylcellulose, lactose monohydrate and part of the microcrystalline cellulose. The mixture is granulated with water in a high shear mixer or fluid bed. The granulate is dried in oven or a fluid bed dryer. Dry mixture is sieved or milled through appropriate mesh size. Microcrystalline cellulose and the remaining hydroxyethylcellulose are mixed with the granulate. At the end sieved magnesium stearate is added and mixed together and tablets are compressed.
  • Hydroxypropyl methylcellulose (type 2208 USP; matrix polymer 100.00
  • hydroxyethylcellulose (Natrosol 250 HHX grade)
  • Tofacitinib is mixed with part of hydro xypropyl methylcellulose, lactose and part of microcrystalline cellulose. The mixture is granulated with water in a high shear mixer or fluid bed. The granulate is dried in oven or a fluid bed dryer. Dry mixture is sieved or milled through appropriate mesh size. Microcrystalline cellulose and the remaining hydroxypropyl methylcellulose and mixed with the granulate.
  • Second layer is added into the die and the bilayer tablet is compressed with compression force ranging from 8 - 23 kN.
  • Lactose, microcrystalline cellulose, hydroxyethylcellulose and tofacitinib citrate were mixed together and sieved through 0.75 mm mesh sieve.
  • the mixture was granulated with water in a high shear mixer of fluid bed.
  • the granulate was dried in oven or fluid bed dryer.
  • the resulting dry mixture was sieved or milled through an appropriate sieve.
  • Carrageenan and magnesium stearate were added and the mixture was additionally blended and tablets were compressed.
  • Table 15 Reference examples 1 - 4 corresponding respectively to example 1, 4, 5 and 9 of WO
  • Reference examples 1 - 4 were tested according to discriminatory dissolution to evaluate mechanical susceptibility of matrix tablets. As it can be appreciated from table 16, drug release from reference samples was much faster under mechanical stress. Drug release from the formulation of reference example 3 was very fast even without mechanical stress so that such formulation cannot even be considered to be a sustained release formulation. Table 16: Drug release in dissolution medium with (MS) or without mechanical stress (No MS) using apparatus I, 100 RPM, 900 ml of pH 6.8 medium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations à libération prolongée comprenant du tofacitinib ou l'un de ses sels pharmaceutiquement acceptables qui démontrent une moindre fluctuation de la concentration du médicament dans le plasma, une libération indépendante du pH, une robustesse mécanique, un effet nul induit par les aliments et qui conviennent pour une administration une fois par jour.
PCT/EP2014/058448 2013-04-26 2014-04-25 Formulations de tofacitinib à libération prolongée Ceased WO2014174073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165577 2013-04-26
EP13165577.1 2013-04-26

Publications (1)

Publication Number Publication Date
WO2014174073A1 true WO2014174073A1 (fr) 2014-10-30

Family

ID=48190278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/058448 Ceased WO2014174073A1 (fr) 2013-04-26 2014-04-25 Formulations de tofacitinib à libération prolongée

Country Status (1)

Country Link
WO (1) WO2014174073A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104459004A (zh) * 2014-12-16 2015-03-25 南京艾德凯腾生物医药有限责任公司 枸橼酸托法替布的含量测定及有关物质检测方法
CN106176640A (zh) * 2014-11-28 2016-12-07 四川海思科制药有限公司 一种含枸橼酸托法替布的药物组合物及其制备方法
CN106389371A (zh) * 2016-11-16 2017-02-15 杭州朱养心药业有限公司 枸橼酸托法替布药物组合物
CN106420648A (zh) * 2016-11-22 2017-02-22 山东淄博新达制药有限公司 枸橼酸托法替布片剂及其制备方法
WO2017029587A1 (fr) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques orales à libération prolongée de tofacitinib
US9937181B2 (en) 2013-03-16 2018-04-10 Pfizer Inc. Tofacitinib oral sustained release dosage forms
CN108066319A (zh) * 2016-11-10 2018-05-25 江苏先声药业有限公司 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
WO2019224058A1 (fr) 2018-05-24 2019-11-28 Synthon B.V. Compositions de tofacitinib à libération contrôlée
CN110787145A (zh) * 2019-12-17 2020-02-14 南京康川济医药科技有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN110891551A (zh) * 2017-07-20 2020-03-17 印塔斯制药有限公司 非脉冲式持续释放倍他司汀口服固体组合物
CN111150711A (zh) * 2018-11-07 2020-05-15 上海博志研新药物技术有限公司 托法替布控释片、制备方法及其应用
CN111184696A (zh) * 2020-02-26 2020-05-22 江苏艾立康药业股份有限公司 一种枸橼酸托法替布缓释片及其制备方法
WO2020138791A3 (fr) * 2018-12-28 2020-08-20 주식회사 대웅제약 Préparation à libération prolongée comprenant du tofacitinib ou un sel pharmaceutiquement acceptable associé et son procédé de fabrication
WO2020194081A1 (fr) * 2019-03-27 2020-10-01 Unichem Laboratories Limited Composition à libération prolongée de tofacitinib
WO2021038014A1 (fr) 2019-08-29 2021-03-04 Synthon B.V. Compositions de tofacitinib à libération contrôlée
WO2021169724A1 (fr) * 2020-02-26 2021-09-02 上海博志研新药物技术有限公司 Forme galénique à libération prolongée de tofacitinib, son procédé de préparation et son application
WO2022254017A1 (fr) 2021-06-04 2022-12-08 Synthon B.V. Compositions de tofacitinib à libération prolongée
US20230270666A1 (en) * 2020-07-28 2023-08-31 Fang Zhou Novel gastroretentive extended release dosage form
CN117100714A (zh) * 2023-10-09 2023-11-24 深圳市瑞华制药技术有限公司 一种枸橼酸托法替布缓释片及其制备方法
WO2024042218A1 (fr) 2022-08-26 2024-02-29 Synthon B.V. Compositions de tofacitinib à libération prolongée sans enrobage fonctionnel
US11976077B2 (en) 2015-10-16 2024-05-07 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
US11993606B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11993605B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12077545B2 (en) 2015-10-16 2024-09-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN120346153A (zh) * 2025-04-18 2025-07-22 上海华茂药业有限公司 一种基于研磨乳糖的缓释口服制剂及其制备方法
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096909A1 (fr) 2001-05-31 2002-12-05 Pfizer Products Inc. Resolution optique de (1-benzyl-4-methylpiperidine-3-yle) methylamine et son utilisation pour la preparation de derives de pyrrolo 2,3-pyrimidine utilises comme inhibiteurs de proteines kinase
WO2003048162A1 (fr) 2001-12-06 2003-06-12 Pfizer Products Inc. Nouveau compose cristallin
WO2007012953A2 (fr) 2005-07-29 2007-02-01 Pfizer Products Inc. Derives de pyrrolo[2,3-d]pyrimidine, leurs intermediaires et leur synthese
WO2012100949A1 (fr) 2011-01-27 2012-08-02 Ratiopharm Gmbh Formes galéniques orales à libération modifiée comprenant du tasocitinib
US20120195966A1 (en) * 2011-01-27 2012-08-02 Frank Sievert Oral dosage form for modified release comprising a jak3 inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096909A1 (fr) 2001-05-31 2002-12-05 Pfizer Products Inc. Resolution optique de (1-benzyl-4-methylpiperidine-3-yle) methylamine et son utilisation pour la preparation de derives de pyrrolo 2,3-pyrimidine utilises comme inhibiteurs de proteines kinase
WO2003048162A1 (fr) 2001-12-06 2003-06-12 Pfizer Products Inc. Nouveau compose cristallin
WO2007012953A2 (fr) 2005-07-29 2007-02-01 Pfizer Products Inc. Derives de pyrrolo[2,3-d]pyrimidine, leurs intermediaires et leur synthese
WO2012100949A1 (fr) 2011-01-27 2012-08-02 Ratiopharm Gmbh Formes galéniques orales à libération modifiée comprenant du tasocitinib
US20120195966A1 (en) * 2011-01-27 2012-08-02 Frank Sievert Oral dosage form for modified release comprising a jak3 inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.A. FINCH: "Hydrophilic polymers", 1987, BLACKIE&SON LTD
M. SIMON: "Ulcerative colitis: medical management", CÔLON & RECTUM, vol. 7, no. 1, 1 February 2013 (2013-02-01), pages 11 - 17, XP055126727, ISSN: 1951-6371, DOI: 10.1007/s11725-013-0434-6 *
NDA 203214 (TOFACITINIB), CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW (S), FDA
S. B. TIWARI; A. R. RAJABI-SIAHBOOMI: "Extended-release oral drug delivery technologies: Monolithic Matrix systems", METHODS IN MOLECULAR BIOLOGY, DRUG DELIVERY SYSTEMS, vol. 437, pages 217 - 243, XP009165010, DOI: doi:10.1007/978-1-59745-210-6_11

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11253523B2 (en) 2013-03-16 2022-02-22 Pfizer Inc. Tofacitinib oral sustained release dosage forms
US10639309B2 (en) 2013-03-16 2020-05-05 Pfizer Inc. Tofacitinib oral sustained release dosage forms
US9937181B2 (en) 2013-03-16 2018-04-10 Pfizer Inc. Tofacitinib oral sustained release dosage forms
CN106176640B (zh) * 2014-11-28 2019-12-20 四川海思科制药有限公司 一种含枸橼酸托法替布的药物组合物及其制备方法
CN106176640A (zh) * 2014-11-28 2016-12-07 四川海思科制药有限公司 一种含枸橼酸托法替布的药物组合物及其制备方法
CN104459004A (zh) * 2014-12-16 2015-03-25 南京艾德凯腾生物医药有限责任公司 枸橼酸托法替布的含量测定及有关物质检测方法
WO2017029587A1 (fr) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques orales à libération prolongée de tofacitinib
US12110297B2 (en) 2015-10-16 2024-10-08 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12116373B2 (en) 2015-10-16 2024-10-15 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12103933B2 (en) 2015-10-16 2024-10-01 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12091415B2 (en) 2015-10-16 2024-09-17 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12134621B2 (en) 2015-10-16 2024-11-05 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12077545B2 (en) 2015-10-16 2024-09-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11993605B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11993606B2 (en) 2015-10-16 2024-05-28 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11976077B2 (en) 2015-10-16 2024-05-07 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN108066319B (zh) * 2016-11-10 2022-01-14 江苏先声药业有限公司 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
CN108066319A (zh) * 2016-11-10 2018-05-25 江苏先声药业有限公司 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
CN106389371A (zh) * 2016-11-16 2017-02-15 杭州朱养心药业有限公司 枸橼酸托法替布药物组合物
CN106420648A (zh) * 2016-11-22 2017-02-22 山东淄博新达制药有限公司 枸橼酸托法替布片剂及其制备方法
CN110891551A (zh) * 2017-07-20 2020-03-17 印塔斯制药有限公司 非脉冲式持续释放倍他司汀口服固体组合物
WO2019224058A1 (fr) 2018-05-24 2019-11-28 Synthon B.V. Compositions de tofacitinib à libération contrôlée
CN111150711A (zh) * 2018-11-07 2020-05-15 上海博志研新药物技术有限公司 托法替布控释片、制备方法及其应用
CN111150711B (zh) * 2018-11-07 2023-04-07 上海博志研新药物技术有限公司 托法替布控释片、制备方法及其应用
WO2020138791A3 (fr) * 2018-12-28 2020-08-20 주식회사 대웅제약 Préparation à libération prolongée comprenant du tofacitinib ou un sel pharmaceutiquement acceptable associé et son procédé de fabrication
WO2020194081A1 (fr) * 2019-03-27 2020-10-01 Unichem Laboratories Limited Composition à libération prolongée de tofacitinib
WO2021038014A1 (fr) 2019-08-29 2021-03-04 Synthon B.V. Compositions de tofacitinib à libération contrôlée
CN110787145A (zh) * 2019-12-17 2020-02-14 南京康川济医药科技有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN111184696A (zh) * 2020-02-26 2020-05-22 江苏艾立康药业股份有限公司 一种枸橼酸托法替布缓释片及其制备方法
WO2021169724A1 (fr) * 2020-02-26 2021-09-02 上海博志研新药物技术有限公司 Forme galénique à libération prolongée de tofacitinib, son procédé de préparation et son application
EP4188366A4 (fr) * 2020-07-28 2024-09-04 Novelstar Pharmaceuticals, Inc. Nouvelle forme galénique à libération prolongée à rétention gastrique
US11844866B2 (en) * 2020-07-28 2023-12-19 Novelstar Pharmaceuticals, Inc. Gastroretentive extended release dosage form
US20230270666A1 (en) * 2020-07-28 2023-08-31 Fang Zhou Novel gastroretentive extended release dosage form
US20240382427A1 (en) * 2020-07-28 2024-11-21 Novelstar Pharmaceuticals, Inc. Novel gastroretentive extended release dosage form
WO2022254017A1 (fr) 2021-06-04 2022-12-08 Synthon B.V. Compositions de tofacitinib à libération prolongée
WO2024042218A1 (fr) 2022-08-26 2024-02-29 Synthon B.V. Compositions de tofacitinib à libération prolongée sans enrobage fonctionnel
CN117100714A (zh) * 2023-10-09 2023-11-24 深圳市瑞华制药技术有限公司 一种枸橼酸托法替布缓释片及其制备方法
CN120346153A (zh) * 2025-04-18 2025-07-22 上海华茂药业有限公司 一种基于研磨乳糖的缓释口服制剂及其制备方法

Similar Documents

Publication Publication Date Title
WO2014174073A1 (fr) Formulations de tofacitinib à libération prolongée
US6881420B2 (en) Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
WO2002070021A1 (fr) Composition d'administration par voie gastrique d'agents anticancereux et methodes de traitement par inhibition de cellules cancereuses les utilisant
CZ2003199A3 (cs) Rychle expandující kompozice pro řízené uvolňování léčiva a retenci léčiva v žaludku a lékové formy obsahující tuto kompozici
JP2005516020A (ja) ゼロ次持続放出剤形およびその製造方法
AU2018202652A1 (en) Gastro-retentive drug delivery system
WO2006082523A2 (fr) Compositions pharmaceutiques de metformine
JP2011513498A (ja) 弱塩基性薬物と有機酸とを含む薬物送達システム
CA2790164A1 (fr) Methode de traitement d'une affection sensible a une therapie par baclofene
US11744803B2 (en) PH-controlled pulsatile delivery system, methods for preparation and use thereof
WO2004019901A2 (fr) Composition pharmaceutique a liberation prolongee
CN107530337B (zh) 治疗方法
JP2024501051A (ja) 持続放出ウパダシチニブ配合物
BRPI0615014A2 (pt) composição farmacêutica sólida compreendendo 1-(4-cloroanilino)-4-(4-piridilmetil)ftalazina e um modificador de ph e uso da mesma
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
US20230181479A1 (en) Polymer based formulation for release of drugs and bioactives at specific git sites
KR20110130382A (ko) 생체접착성 컴팩트 매트릭스의 제조방법
KERALIYA et al. Formulation and evaluation of atenolol pulsatile press coated tablets using rupturable and erodible polymers
JP6757596B2 (ja) 内服固形錠剤
Kumar Design, Development and Characterization of Verapamil Hydrochloride Pulsincap: In Vitro and In Vivo
Chaudhari et al. Pelletization techniques: Novel approach for drug delivery
KR102039345B1 (ko) 프레가발린 함유 고팽윤성 서방성 삼중정제
Saharan Novel Fast Dissolving/Disintegrating Dosage Forms
RANOLAZINE Reg. No. 26106507

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14720105

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14720105

Country of ref document: EP

Kind code of ref document: A1